natgillin/translations-raw huggingface dataset:
between 1 kN/cm and 20 kN/cm, at a compaction speed of the compaction rolls 
između 1 kN/cm i 20 kN/cm, uz brzinu zbijanja valjaka za zbijanje:
varistor (MOVs) as an activation component (33) to be placed inside and/or in contact directly or indirectly with the chemical mixture (34), 
promjenjivi otpornik (MOVs) kao aktivacijsku komponentu (33) za stavljanje u i/ili u izravan ili neizravan kontakt s kemijskom mješavinom (34),
A neutralising antibody according to claim 4 where the antibody fragment is a Fab, Fab', F(ab')2, scFv or an epitope-binding fragment thereof. 
Neutralizirajuće antitijelo prema patentnom zahtjevu 4, naznačeno time da je fragment antitijela Fab, Fab', F(ab')2, scFv ili epitopska veza fragmenta iste.
A pharmaceutical composition according to claim 14, additionally comprising other active ingredients. 
Farmaceutski sastav prema patentnom zahtjevu 14, naznačen time da dodatno sadrži druge aktivne sastojke.
is selected from the structures: 
izabran iz struktura:
wherein the term "aryl", alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner and wherein any aryl may have 1 or more substituents independently selected from C1-C6 alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and C1-C6 alkylamino. 
[image] [image] [image] [image] gdje izraz "aril", pojedinačno ili u kombinaciji, označava karbociklički aromatični sustav koji sadrži jedan ili dva prstena pri čemu takvi prstenovi mogu biti spojeni i gdje aril može imati 1 ili više supstituenata nezavisno izabranih od C1-C6 alkila, hidroksila, halo, haloalkila, nitro, cijano, alkoksi i C1-C6 alkilamina.
A compound of any one of claims 1 to 14, wherein the compound or pharmaceutically acceptable salt thereof is in the form of a solid, semi-solid, or liquid dosage form. 
Spoj prema bilo kojem od patentnih zahtjeva od 1 do 14, naznačen time da se spoj ili njegova farmaceutski prihvatljiva sol u obliku čvrstog, polučvrstog ili tekućeg oblika davanja.
A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav koji sadrži učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva od 1 do 14 ili njegovu farmaceutski prihvatljivu sol.
a plurality of active agent particles comprising an active agent selected from glycopyrrolate and formoterol and any pharmaceutically acceptable salts, esters, enantiomers, mixtures of enantiomers or solvates thereof; and a plurality of respirable suspending particles which are perforated microstructures comprising DSPC (1,2-disteroyl-sn-glycero-3-phosphocholine) and calcium chloride, and wherein the plurality of active agent particles co-locate with the plurality of suspending particles within the suspension medium to form a co-suspension. The pharmaceutical composition according to claim 1, wherein the active agent particles comprise glycopyrrolate, including any pharmaceutically acceptable salts, esters, enantiomers, mixtures of enantiomers or solvates thereof. 
čestice više aktivnih sredstava koje sadrže kombinaciju aktivnih sredstava koja se bira između (a) kombinacije formoterola i budesonida ili soli, estera, solvata, enantiomera i smjesa odgovarajućih enantiomera, te (b) kombinacije glikopirolata, formoterola i budesonida, ili soli, estera, solvata, enantiomera i smjesa odgovarajućih enantiomera; i više suspendirajućih čestica pogodnih za respiraciju, gdje se više suspendirajućih čestica pogodnih za respiraciju ko-lociraju sa česticama više aktivnih sredstava unatoč razlikama u uzgonu između čestica aktivnog sredstva i suspendirajućih čestice u mediju za suspenzije gdje suspendirajuće čestice pogodne za respiraciju perforirane mikrostrukture koje sadrže DSPC (1,2-disteroil-sn-glicero-3-fosfokolin) i kalcijev klorid.
The pharmaceutical composition according to claim 1, wherein the suspending particles remain co-located with the active agent particles even when subjected to buoyancy forces amplified by centrifugation at an acceleration selected from accelerations of at least 1 g, at least 10 g, at least 50 g, and at least 100 g. 
Ko-suspenzija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što suspendirajuće čestice ostaju ko-locirane s česticama aktivnog sredstva čak i kada ih se podvrgava uzgonskim silama uvećanim centrifugiranjem uz ubrzanje koje se bira između ubrzanja od najmanje 1 g, najmanje 10 g, najmanje 50 g, te najmanje 100 g.
The pharmaceutical composition according to claim 16 wherein the pharmaceutically acceptable salt of formoterol is selected from hydrochloric, hydrobromic, sulphuric, phosphoric acids, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 
Ko-suspenzija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se farmaceutski prihvatljiva sol formoterola bira između soli klorovodične, bromovodične, sumporne, fosforne, fumarne, maleinske, octene, mliječne, limunske, vinske, askorbinske, jantarne, glutarne, glukonske, trikarbalilne, oleinske, benzojeve, p-metoksibenzojeve, salicilne, o- i p-hidroksibenzojeve, p-klorbenzojeve, metansulfonske, p-toluensulfonske i 3-hidroksi-2-naftalenkarboksilne kiseline.
A pharmaceutical composition for use according to claim 25, wherein the pulmonary disease or disorder is selected from at least one of asthma, COPD, chronic bronchitis, emphysema, bronchiectasis, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary inflammation associated with cystic fibrosis, and pulmonary obstruction associated with cystic fibrosis. 
Ko-suspenzija namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se plućna bolest ili poremećaj bira između najmanje jednog od astme, COPD, pogoršanja preosjetljivosti dišnih puteva kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, respiratornog distresnog sindroma, plućne hipertenzije, te upale pluća i opstrukcije povezane s cističnom fibrozom.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyurea to reduce the number of nocturnal voids in a male patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 25 µg or 50 µg, wherein the dose is measured as the free base of desmopressin, for administration prior to bedtime. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja nokturije ili noćne poliurije, za smanjenje broja noćnih pražnjenja mjehura kod pacijentice, koja treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina u količini od 25 µg za administraciju prije počinka, naznačen time da se doza mjeri kao slobodna baza dezmopresina.
The pharmaceutical composition according to claim 9, wherein the suspending particles are included in the suspension medium at a concentration selected from between 1 mg/ml and 15 mg/ml, between 3 mg/ml and 10 mg/ml, between 5 mg/ml and 8 mg/ml, and about 6 mg/ml. 
Ko-suspenzija u skladu s patentnim zahtjevom 3, naznačena time što su suspendirajuće čestice uključene u medij za suspenzije u koncentraciji koja se bira između od 1 mg/ml do 15 mg/ml, 3 mg/ml do 10 mg/ml, te 1,5 mg/ml do 10 mg/ml.
The composition for use according to any one of claims 1 to 3, wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
Pripravak za uporabu prema zahtjevu 1, 2 ili 3, naznačen time da je doza slobodne baze dezmopresina u obliku acetatne soli dezmopresina.
A compound selected from: 
Spoj koji ima formulu Ia:
or having formula Ic: 
[image] ili ima formulu Ic:
or having formula Id: 
[image] ili ima formulu Id:
or having formula Ie: 
[image] ili ima formulu Ie:
A co-suspension according to claim 15, wherein the suspending particles are included in the suspension medium at a concentration selected from between 1 mg/mL to 15 mg/mL, 3 mg/mL to 10 mg/mL, 1.5 mg/mL to 10 mg/mL. 
Ko-suspenzija u skladu s patentnim zahtjevom 3, naznačena time što su suspendirajuće čestice uključene u medij za suspenzije u koncentraciji koja se bira između od 1 mg/ml do 15 mg/ml, 3 mg/ml do 10 mg/ml, te 1,5 mg/ml do 10 mg/ml.
less than 10% particles smaller than 10 microns; 
manje od 10% čestica manje je od 10 mikrona;
a d0.5 value in the range of 60-130 microns. 
vrijednost d0,5 u rasponu od 60 do 130 mikrona.
The composition according to claim 1, wherein the solution comprising the polymer and the water-miscible solvent has a viscosity in the range of 0.7-2.0 Pa.s. 
Sastav u skladu sa zahtjevom 1, pri čemu se otopina sadrži polimer, a otapalo mješljivo s vodom ima viskozitet u rasponu od 0,7 do 2,0 Pa.s.
The composition according to claim 3, wherein the drug/polymer mass ratio is about 33%. 
Sastav u skladu sa zahtjevom 3 gdje je omjer mase lijeka/polimera otprilike 33%.
The composition according to any one of the previous claims, wherein the solubility of the drug in the solvent is lower than 90 mg/ml. 
Sastav u skladu s jednim od prethodnih zahtjeva, pri čemu je topivost lijeka u otapalu manja od 90 mg/ml.
The composition according to claim 5, wherein the solubility of the drug in the solvent is lower than 10 mg/ml. 
Sastav u skladu sa zahtjevom 5, gdje je topljivost lijeka u otapalu manja od 10 mg/ml.
The composition according to any one of the previous claims wherein the solvent/drug mass ratio is lower than 11.4% wt/wt, expressed as the weight percent of solvent with respect to drug. 
Sastav u skladu s bilo kojim od prethodnih zahtjeva pri čemu je omjer mase otapala/lijeka niži od 11,4% težinskog faktora/težinskog faktora izražen kao postotak težine otapala s obzirom na lijek.
The composition according to any of the previous claims further comprising Mg(OH)2 in a molar ratio between 2/3 and 2/5, expressed as the molar ratio of drug to Mg(OH)2. 
Sastav u skladu s bilo kojim od prethodnih zahtjeva nadalje sadržava Mg(OH)2 u molarnom omjeru između 2/3 i 2/5, izražen kao molarni omjer lijeka naspram Mg(OH)2.
A pharmaceutical kit for the in situ formation of a biodegradable implant in a body comprising the composition of any one of claims 1-12, wherein the drug and the biocompatible polymer are contained in a first container, and the water-miscible solvent is contained in a second, separate container. 
Farmaceutski komplet za in situ formiranje biorazgradivog implantata u tijelu koji sadržava sastav iz bilo kojeg od prethodnih zahtjeva 1 do 12, pri čemu se lijek i biokompatibilni polimer nalaze u prvom spremniku, a otapalo mješljivo s vodom nalazi se u drugom, zasebnom spremniku.
"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, 
"heteroaril" znači bilo koja mono- ili bi-ciklička skupina sastavljena od 5 do 10 članova prstena, koja ima najmanje jednu aromatsku polovicu koja sadrži od 1 do 3 heteroatoma odabrana od kisika, sumpora i dušika,
"cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, 
"cikloalkil" znači bilo koja mono- ili bi-ciklička ne-aromatska karbociklička skupina koja sadrži od 3 do 10 članova prstena,
Compounds according to claim 1 wherein at least one of the groups selected from R1, R2 and R3 does not represent a hydrogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da najmanje jedna od skupina odabrana od R1, R2 i R3 ne predstavlja atom vodika.
Compounds according to claim 1 wherein X represents a carbon atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da X predstavlja atom ugljika.
Compounds according to claim 1 wherein R6 represents a hydrogen atom, a optionally substituted linear or branched (C1-C8)alkyl group or an heteroarylalkyl(C1-C6) group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R6 predstavlja atoma vodika, po izboru supstituiranu ravnu ili razgrananu (C1-C8)alkilnu skupinu ili heteroarilalkil(C1-C6) skupinu.
Compounds according to claim 1 wherein R7 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, an aryl or an heteroaryl group. 
Spojevi u skladu s patentnim zahtjevom 1 naznačeni time, da R7 predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu, ravnu ili razgrananu (C2-C6)alkenilnu skupinu, ravnu ili razgrananu (C2-C6)alkinilnu skupinu, arilnu ili heteroarilnu skupinu.
Compounds according to claim 1 wherein R8 and R8' independently of one another represent a linear or branched (C1-C6)alkyl group, or (R8, R8') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C1-C6)alkyl group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R8 i R8' neovisno jedan od drugoga predstavljaju ravnu ili razgrananu (C1-C6)alkilnu skupinu ili (R8, R8') tvore zajedno s atomom dušika koji ih nosi ne-aromatski prsten sastavljen od 5 do 7 članova prstena, koji dodatno mogu, osim atoma dušika, dodatno sadržavati od jedan do 3 heteroatoma odabrana od kisika, sumpora i dušika, pri čemu je jasno da se predmetni dušik može supstituirati skupinom koja predstavlja atom vodika, ravnom ili razgrananom (C1-C6)alkilnom skupinom.
Compounds according to claim 15 wherein R9 represents -Cy1-Cy2 in which Cy1 represents a pyrimidinyl group and Cy2 represents a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group, or a cyclopropyl group. 
Spojevi u skladu s patentnim zahtjevom 15, naznačeni time, da R9 predstavlja -Cy1Cy2 gdje Cy1 predstavlja pirimidinil skupinu a Cy2 predstavlja fenilnu skupinu, skupinu piridinila, skupinu pirazolila, skupinu morfolinila, skupinu furanila ili skupinu ciklopropila.
Use of a pharmaceutical composition according to claim 37 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 37, naznačena time, da je za proizvodnju lijekova za uporabu u liječenju karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, jednjaka i jetre, limfoblastične leukemije, akutne mijeloidne leukemije, limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka gušterače i raka pluća malih stanica.
Compound of formula (I) according to any one of claims 1 to 34, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 34 ili adicijske soli istog s farmaceutski prihvatljivom kiselinom ili lužinom, naznačena time, da se koristi u liječenju karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, jednjaka i jetre, limfoblastične leukemije, akutne mijeloidne leukemije, limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka gušterače i raka pluća malih stanica.
Use of a compound of formula (I) according to any one of claims 1 to 34 or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Uporaba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 34 ili adicijske soli istog s farmaceutski prihvatljivom kiselinom ili lužinom, naznačena time, da se koristi u proizvodnji lijeka za liječenje karcinoma mokraćnog mjehura, mozga, dojki i maternice, kronične limfoidne leukemije, raka debelog crijeva, jednjaka i jetre, limfoblastične leukemije, akutne mijeloidne leukemije, limfoma, melanoma, maligne hemopatije, mijeloma, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka gušterače i raka pluća malih stanica.
wherein the pH employed in step i) is 7.0 to 10.0, when the physiologically active polypeptide is an exendin, oxyntomodulin, GLP-1, GLP-2 or one of the derivatives thereof, and wherein the pH employed in step i) is 4.0 to 10.0 when the physiologically active polypeptide is human insulin or a derivative thereof. 
dok je pH u koraku i) namješten na 7,0 do 10,0, kada je fiziološki djelotvorni polipeptid eksendin, oksintomodulin, GLP-1, GLP-2 ili jedan od njihovog derivata, i pri čemu je pH u koraku i) namješten na 4,0 do 10,0 kada je fiziološki djelotvorni polipeptid ljudski inzulin ili njegov derivat.
The method of claim 1, wherein the alcohol is present in the reaction medium, in an amount of 35% to 60% by volume, based on the total amount of the reaction medium. 
Postupak prema zahtjevu 1, naznačen time, da je alkohol prisutan u reakcijskom mediju, u količini od 35% do 60% po volumenu, na osnovi ukupne količine reakcijskog medija.
characterised in that said solvent is DMSO the biocompatible polymer has an intrinsic inherent viscosity in the range of 0.16-0.60 dl/g measured in chloroform at 25°C and a 0.1% concentration; and the concentration of the biocompatible polymer is comprised in the range 25%-50%, percentage of polymer weight based on total polymeric solution; 
barem otapalo mješljivo s vodom s dipolnim momentom u rasponu od 3,9-43 D, naznačeno time što je spomenuto otapalo DMSO biokompatibilni polimer ima intrinzičnu inherentnu viskoznost u rasponu od 0,16-0,60 dl/g mjerenu u kloroformu pri 25°C i pri koncentraciji od 0,1%; a koncentracija biokompatibilnog polimera sadržana je u rasponu od 25%-50%, a postotak težine polimera na temelju ukupne otopine polimera;
the viscosity of the solution comprising the polymer and the solvent is between 0.5 and 7.0 Pa.s; and the particle size distribution of the drug is as follows: 
viskozitet otopine koja se sastoji od polimera i otapala je između 0,5 i 7,0 Pa.s; i distribucija veličine čestica lijeka je sljedeća:
The composition according to any of the previous claims irradiated in the range 5-25 KGy. 
Sastav u skladu s bilo kojim od prethodnih zahtjeva ozračen u rasponu od 5-25 KGy.
The pharmaceutical kit according to claim 14, wherein the containers are connectable through a connector device. 
Farmaceutski komplet u skladu sa zahtjevom 14 pri čemu se spremnici mogu spojiti kroz uređaj za spajanje.
a reel (B), on which the deformable closing band (E) is wound, 
kolut (B), na koji je traka promjenjiva oblika (E) namotana,
a shaping seat (3) for shaping the closing band (E), 
mjesto za oblikovanje (3) za oblikovanje trake za zatvaranje (E),
a cutting seat (7) for cutting a portion (P) of the closing band (E) at a predetermined length, 
mjesto za rezanje (7) za rezanje dijela (P) trake za zatvaranje (E) na predodređenu duljinu,
means (9) for cutting and shaping the portion (P) of the band (E), 
sredstva (9) za rezanje i oblikovanje (P) trake (E),
the plate (5) is horizontal and is anchored to the supporting frame (2), 
ploča (5) je horizontalna i usidrena u potporni okvir (2),
the means (9) for cutting and shaping the portion (P) of the band (E) are placed in the cutting seat (7), 
sredstva (9) za rezanje i oblikovanje dijela (P) spremnika (E) smještena su u mjesto za rezanje (7),
the actuating means (11) are exclusively actuated by an electric motor(15), 
sredstva za pokretanje (11) isključivo se pokreću pomoću električnog motora (15),
Machine as claimed in claim 1, characterized in that said electric motor (15) is mounted on said frame (2). 
Uređaj sukladno zahtjevu 1, naznačen time što je navedeni eletrični motor (15) smješten u navedeni okvir (2).
A process for the production of primycin or primycin components, wherein said primycin components are compounds of formula (I) wherein 
Postupak za proizvodnju primicina ili komponenata primicina, gdje su navedene komponente primicina tvari formule (I) [image] gdje
is H, OH or a group of formula (A) X- is either an acid residue of an inorganic acid or an acid residue of an organic acid, said process comprising the steps of fermenting a microorganism selected from the group consisting of Saccharomonospora azurea, variant strains and mutants thereof on a culture medium, and after achieving the appropriate concentration, recovering primycin or primycin component by a known process or a combination of known processes. 
je H, OH ili grupa formule (A) [image] X- je bilo kiselinski ostatak anorganske kiseline ili kiselinski ostatak organske kiseline, navedeni postupak obuhvaća korake fermentiranja mikroorganizma odabranog iz grupe koja se sastoji od Saccharomonospora azurea, različitih sojeva i njihovih mutanata u mediju za kultiviranje, a nakon toga postizanje odgovarajuće koncentracije, obnavljanje primicina ili komponente primicina poznatim postupkom ili kombinacijom poznatih postupaka.
A process according to Claim 1, wherein as culture medium a medium containing organic carbon source, organic nitrogen source, mineral salts and preferably natural or synthetic fats, oils, fatty alcohols and/or fatty acids is used. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu se kao medij za kultiviranje koristi medij koji sadrži izvor organskog ugljika, izvor organskog dušika, mineralne soli i poželjno prirodne ili sintetske masti, ulja, masne alkohole i/ili masne kiseline.
A process according to Claims 1 or 2, wherein said fatty acid is stearic acid. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedena masna kiselina stearinska kiselina.
A process according to Claims 1 to 3, wherein the fermentation is carried out at a temperature of 18 to 35°C, at a pH value of 6 to 9 for at least 48 hours. 
Postupak u skladu s patentnim zahtjevima 1 ili 3, pri čemu se fermentacija provodi kod temperature od 18 do 35°C, kod pH vrijednosti 6 do 9 tijekom najmanje 48 sati.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačena/e time, da se upotrebljava(ju) u liječenju i/ili prevenciji autoimunog hepatitisa.